Skip to main content
Nature Communications logoLink to Nature Communications
. 2024 Jun 18;15:5177. doi: 10.1038/s41467-024-49655-6

Author Correction: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population

William Wang 1, Nora D Volkow 2,, Nathan A Berger 1, Pamela B Davis 3, David C Kaelber 4, Rong Xu 5,
PMCID: PMC11189541  PMID: 38890337

Correction to: Nature Communications 10.1038/s41467-024-48780-6, published online 28 May 2024

In this article in the abstract the word clinical was misspelt as clinicl. Additionally, on page 2 of the article the sentence ‘Compared to naltrexone or topiramate, semaglutide was associated with a significantly lower risk of incident AUD diagnosis’ was incorrect and should have been ‘Compared to naltrexone or topiramate, semaglutide was associated with a significantly lower risk of recurrent AUD diagnosis’. Finally, on page 8 the sentence ‘Fourth the follow-up time for the main analyses was 8 months’ should have read ‘Fourth the follow-up time for the main analyses was 12 months.’ The original article has been corrected.

Contributor Information

Nora D. Volkow, Email: nvolkow@nida.nih.gov

Rong Xu, Email: rxx@case.edu.


Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES